Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma. Methods This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m 2 by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m 2 by body surface area once every 4 weeks; intravenous topotecan 4 mg/m 2 by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, and is active but not recruiting. Findings Between Feb 27, 2014, and April 10, 2018, 260 patients were enrolled and randomly assigned to the trametinib group (n=130) or the standard-of-care group (n=130). At the primary analysis, there were 217 progression-free survival events (101 [78%] in the trametinib group and 116 [89%] in the standard-of-care group). Median progression-free survival in the trametinib group was 13·0 months (95% CI 9·9–15·0) compared with 7·2 months (5·6–9·9) in the standard-of-care group (hazard ratio 0·48 [95% CI 0·36–0·64]; p<0·0001). The most frequent grade 3 or 4 adverse events in the trametinib group were skin rash (17 [13%] of 128), anaemia (16 [13%]), hypertension (15 [12%]), diarrhoea (13 [10%]), nausea (12 [9%]), and fatigue (ten [8%]). The most frequent grade 3 or 4 adverse events in the standard-of-care group were abdominal pain (22 [17%]), nausea (14 [11%]), anaemia (12 [10%]), and vomiting (ten [8%]). There were no treatment-related deaths. Interpretation Trametinib represents a new standard-of-care option for patients with recurrent low-grade serous carcinoma. Funding NRG Oncology, Cancer Research UK, Target Ovarian Cancer, and Novartis.
Source: The Lancet
Authors: David M Gershenson, Austin Miller, William E Brady, James Paul, Karen Carty, William Rodgers, David Millan, Robert L Coleman, Kathleen N Moore, Susana Banerjee, Kate Connolly, Angeles Alvarez Secord, David M O'Malley, Oliver Dorigo, Stephanie Gaillard, Hani Gabra, Brian Slomovitz, Parviz Hanjani, John Farley, Michael Churchman, Ailith Ewing, Robert L Hollis, C Simon Herrington, Helen Q Huang, Lari Wenzel, Charlie Gourley
Institutions: The University of Texas MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, NRG Oncology, Cancer Research UK, University of Glasgow, Cornell University, Weill Cornell Medicine, Queen Elizabeth University Hospital, OU Health Stephenson Cancer Center, University of Oklahoma, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, Duke University, Duke Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Stanford Cancer Institute, Stanford University, Sidney Kimmel Comprehensive Cancer Center, Imperial College London, Mount Sinai Medical Center, Abington Memorial Hospital, St. Joseph's Hospital and Medical Center, Western General Hospital, Institute of Genetics and Cancer, MRC Human Genetics Unit, University of Edinburgh, University of California, Irvine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: trametinib, low-grade serous carcinoma, recurrent ovarian cancer, MEK inhibitors, MAPK signaling, progression-free survival, paclitaxel, pegylated liposomal doxorubicin, topotecan, letrozole, tamoxifen, standard of care, platinum-refractory disease, endometrioid carcinoma, serous borderline tumor
Open Access status: hybrid
Estimated APC paid: $6,500
Funders: Cancer Research Institute, GlaxoSmithKline, Northwestern University, University of Rochester, Dartmouth College, National Cancer Research Institute, NorthShore University HealthSystem, NRG Oncology, Cancer Research UK, University of Texas MD Anderson Cancer Center, University of North Carolina at Chapel Hill, Palo Alto Medical Foundation, Medical Research Council, National Cancer Institute
Awards: Precision medicine and the mutational landscape of high grade serous ovarian cancer, NRG Oncology Network Group Operations Center, OSU as a Network Lead Academic Participating Site for the NCI NCTN, G7097155749, G8078713348, Cancer Center Support Grant, Cancer Center Support Grant, Cancer Center Support Grant, Cancer Center Support Grant (CCSG), NRG Oncology - Statistical and Data Management Center
OpenAlex ID: W4210288145
